PMC5281641_01
Time course of impedances of a typical cochlear implant (CI) electrode (no. 6) together with the times of systemic and local glucocorticoid application in patient 1 from the case reports. HD high dose
106_2016_285_Fig2_HTML.jpg
PMC5281641_02_106_2016_285_Fig2_HTML.jpg
Fig2
Implantation of single parts (size about 3 mm x 0.46 mm, each) of a biocompatible, degradable drug carrier approved for intravitreal injection (Ozurdex , arrows) in addition to the cochlear implant electrode carrier in the scala tympani in patient 1 (see case reports). a Endoscopic view of the middle ear. Insertion of one half (a, b) and then of the other half (c) of the degradable drug-delivery system. d Sealing of the insertion point of the electrode carrier into the scala tympani with connective tissue. LPI long process of the incus; Ch. t. chorda tympani; E.p. eminentia pyramidalis
106_2016_285_Fig3_HTML.jpg
PMC5281641_02_106_2016_285_Fig3_HTML.jpg
Fig3
PMC5281641_02
Time course of impedances of a typical cochlear implant (CI) electrode (no. 6) together with the times of systemic and local glucocorticoid application in patient 1 from the case reports. HD high dose
106_2016_285_Fig2_HTML.jpg
PMC5281641_02_106_2016_285_Fig2_HTML.jpg
Fig2
Implantation of single parts (size about 3 mm x 0.46 mm, each) of a biocompatible, degradable drug carrier approved for intravitreal injection (Ozurdex , arrows) in addition to the cochlear implant electrode carrier in the scala tympani in patient 1 (see case reports). a Endoscopic view of the middle ear. Insertion of one half (a, b) and then of the other half (c) of the degradable drug-delivery system. d Sealing of the insertion point of the electrode carrier into the scala tympani with connective tissue. LPI long process of the incus; Ch. t. chorda tympani; E.p. eminentia pyramidalis
106_2016_285_Fig3_HTML.jpg
PMC5281641_02_106_2016_285_Fig3_HTML.jpg
Fig3
Time course of the impedances of a typical cochlear implant (CI) electrode (no. 9) together with the times of medical and surgical interventions in patient 2 (see case reports). HD high dose
106_2016_285_Fig4_HTML.jpg
PMC5281641_02_106_2016_285_Fig4_HTML.jpg
Fig4
Calculated concentration in the perilymph for intratympanic injection (extracochlear application) of dexamethasone phosphate solution (1x per day, every 2 days, total of 5 injections). ST scala tympani
106_2016_285_Fig5_HTML.jpg
PMC5281641_02_106_2016_285_Fig5_HTML.jpg
Fig5
Calculated concentration of dexamethasone in the perilymph for extracochlear application of Ozurdex  to the round window membrane. ST scala tympani
106_2016_285_Fig6_HTML.jpg
PMC5281641_02_106_2016_285_Fig6_HTML.jpg
Fig6
Calculated concentration of dexamethasone in the perilymph for intracochlear application of Ozurdex  in addition to a cochlear implant electrode carrier (Nucleus CI24RE(CA)) in the basal part of the basal turn of the scala tympani (case report 1). ST scala tympani
106_2016_285_Fig7_HTML.jpg
PMC5281641_02_106_2016_285_Fig7_HTML.jpg
Fig7